NCT02887443View on ClinicalTrials.gov

A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a Substrate

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Drug-Drug Interaction
Interventions
DRUG

Raxone (idebenone 150 mg)

Raxone (idebenone 300 mg t.i.d.) on days 3 and days 5 to 10

DRUG

Midazolam 2,5 mg

Midazolam (2,5 mg single oral dose) on days 1, 3 and 10

Trial Locations (1)

38610

Eurofins Optimed, Gières

Sponsors
All Listed Sponsors
lead

Santhera Pharmaceuticals

INDUSTRY

NCT02887443 - A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a Substrate | Biotech Hunter | Biotech Hunter